Orchid receives US FDA approval for Cefdinir

New Delhi, July 20: Pharma company Orchid Chemicals and Pharmaceuticals Ltd today said it has received US Food and Drug Administration (FDA) approval for Cefdinir capsules and oral suspension.

The capsule will be available in 300 mg and the oral suspension in 25 mg, 5 ml and 250 mg/5 ml variants.

Cefdinir is a life saving cephalosporin antibiotic drug which became generic only recently. The product had a retail market sale of around one billion dollars prior to patent expiry in May 2007, a press release said.

''We are happy that our Cefdinir ANDAs have received the US FDA nod and that both the dosage forms of this product have been approved. This is indeed a significant approval in our product strategy for the US generics market,'' company's Managing Director K Raghavendra Rao said.

We would be launching this product soon and are confident of achieving a robust market share and revenue profile from this quarter onwards, he added.

UNI